NR3C2 and type 2 diabetes mellitus: Nonsteroidal mineralocorticoid receptor antagonist could be used in 1334 adults (14.01%) with T2D, an eGFR >25 mL/min/1.73 m2, normal serum potassium concentration and albuminuria (>30 mg/g).